PFE Reports earnings results
Summary
On August 4, 2026, Pfizer Inc. (NYSE: PFE) reported its second-quarter 2026 financial results via Exhibit 99. The company raised its full-year 2026 Revenue guidance by $500 million at the midpoint, while reaffirming Adjusted diluted EPS guidance, which absorbs a $0.10 impact from the Innovent Biologics, Inc. transaction. Operational revenue growth of launched and acquired products was 18%. Pfizer also announced the expansion of Productivity Enhancement Initiatives.
Why It Matters
Investors should note Pfizer's decision to raise its full-year 2026 revenue guidance by $500 million at the midpoint (via Ex. 99), signaling positive operational performance and future outlook. The 18% operational revenue growth of launched and acquired products further underscores this strength.
These filing summaries are free and always will be. If this helped you spot material events, consider supporting us.
Want to see how PFE traded around this filing?
Check real-time charts and technical analysis on TradingView to see market reaction to this event.
View PFE Charts on TradingViewAffiliate link
Is this filing part of a pattern?
One disclosure is noise. Get a structured briefing covering 12 months of SEC filings, disclosure signals, and what to watch next.
Filing Details
Reported Items
Additional Information
- CIK Number
- 0000078003
- Filing Date
- Tuesday, August 4, 2026
- Filing Time
- 12:00 AM UTC
- Form Type
- 8-K
- Materiality Level
- high
- Sentiment
- positive